Clinical intelligence
Pipeline watch
Clinical-stage assets, trial phases, expected catalysts and the uncertainties that matter most.
| Asset | Sponsor | Phase | Indication | Reported update | Source date | Main risk |
|---|---|---|---|---|---|---|
| Eloralintide | Eli Lilly and Company | Phase 3 ENLIGHTEN program | Obesity | ENLIGHTEN-1 is a Phase 3 obesity study; a registered study is not evidence of a successful outcome. | 2026-09-23 | Investigational; sponsor reports require full-data review |
| Enicepatide | Roche | Phase 3 obesity; Phase 2 diabetes results | Obesity | Sponsor-reported Phase 2 diabetes results; ENITH-1 and ENITH-2 Phase 3 weight-management studies ongoing. | 2026-09-22 | Investigational; sponsor reports require full-data review |
| Petrelintide | Zealand Pharma / Roche | Phase 3 ZUPREME program | Obesity | Zealand announced initiation of the Phase 3 ZUPREME program for overweight or obesity. | 2026-09-22 | Investigational; sponsor reports require full-data review |
| Zenagamtide | Novo Nordisk | Phase 3 obesity program | Obesity | Sponsor update describes the Phase 3 AMAZE obesity program and planned diabetes development. | 2026-08-05 | Investigational; sponsor reports require full-data review |
| Retatrutide | Eli Lilly and Company | Phase 3 | Obesity | Sponsor-reported Phase 3 results in two additional trials; retatrutide remains investigational. | 2026-07-23 | Investigational; sponsor reports require full-data review |
| Acmopatide | Roche | Phase 2 (April 2026 snapshot) | Type 1 diabetes glycemic-control research | Dated sponsor pipeline lists acmopatide (CT-868) in Phase 2 for type 1 diabetes glycemic control. | 2026-04-23 | Investigational; sponsor reports require full-data review |
| PF-08653944 | Pfizer | Phase 3 program reported | Obesity | Sponsor reported Phase 2b findings and initiation of Phase 3 VESPER-4. Planned trials should not be read as completed trials. | 2026-02-03 | Investigational; sponsor reports require full-data review |